Vetoquinol SA (LON:0O1O)

Market Cap	840.94M +12.9%
Revenue (ttm)	454.08M -0.9%
Net Income	54.10M +4.8%
EPS	4.56 +6.9%
Shares Out	n/a
PE Ratio	15.96
Forward PE	15.36
Dividend	0.81 (1.12%)
Ex-Dividend Date	Jun 3, 2026

Volume	7
Open	86.90
Previous Close	87.10
Day's Range	86.40 - 86.90
52-Week Range	66.30 - 91.20
Beta	0.83
Analysts	n/a
Price Target	n/a
Est. Earnings	Mar 22, 2027

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA operates as a ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1933
• Employees: 2,526
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0O1O

Financial Performance

In 2025, Vetoquinol's revenue was 525.69 million, a decrease of -2.51% compared to the previous year's 539.20 million. Earnings were 57.36 million, a decrease of -2.26%.

Financial numbers in EUR

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error